| WB | 1/1000-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/20-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LDC; LUM; Lumican; SLRR2D;;Lumican |
| WB Predicted band size | Calculated MW: 38 kDa ; Observed MW: 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthesized peptide derived from human Lumican |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于Lumican抗体的3篇参考文献及其摘要概括：
---
1. **标题**: *Lumican regulates collagen fibril assembly: Skin fragility and corneal opacity in the absence of lumican*
**作者**: Chakravarti, S. et al.
**摘要**: 该研究利用Lumican抗体进行免疫定位和蛋白质分析，发现Lumican缺失导致小鼠皮肤脆弱和角膜混浊，揭示了其对胶原纤维组装的关键调控作用。
2. **标题**: *Lumican expression in triple-negative breast cancer*
**作者**: Nikitovic, D. et al.
**摘要**: 通过免疫组化(使用Lumican抗体)分析三阴性乳腺癌组织，发现Lumican在肿瘤基质中高表达，且与患者预后不良及转移风险增加相关。
3. **标题**: *Lumican as a novel predictor of pulmonary fibrosis progression*
**作者**: Karamanou, K. et al.
**摘要**: 研究利用Lumican抗体检测肺纤维化患者样本，发现Lumican在病变区域的异常沉积可能参与纤维化进程，提示其作为疾病进展的生物标志物潜力。
---
**备注**：文献标题与作者为简化示例，实际引用时需根据具体论文信息核对(如年份、期刊)。如需全文细节，建议通过PubMed或Web of Science检索关键词“Lumican antibody”进一步筛选。
Lumican, a member of the small leucine-rich proteoglycan (SLRP) family, plays a critical role in regulating collagen fibril organization and extracellular matrix (ECM) stability. It is expressed in various tissues, including the cornea, skin, and cartilage, and is involved in cell migration, tissue repair, and immune response modulation. Lumican’s core protein (∼38-42 kDa) contains leucine-rich repeats that mediate collagen binding, while its glycosaminoglycan (GAG) chains influence hydration and ECM interactions.
Lumican antibodies are essential tools for studying its biological functions and pathological roles. In research, these antibodies are used in techniques like immunohistochemistry, Western blotting, and ELISA to detect Lumican expression, localization, and post-translational modifications. They have revealed Lumican’s dual role in cancer—acting as a tumor suppressor by inhibiting metastasis in some contexts (e.g., breast cancer) or promoting progression in others (e.g., pancreatic cancer).
Clinically, Lumican antibodies aid in diagnosing corneal diseases, as Lumican mutations are linked to corneal opacity disorders. They also explore Lumican’s potential as a biomarker in fibrosis, osteoarthritis, and wound healing. Commercially available antibodies are often raised against specific epitopes (human, mouse, or recombinant proteins) and validated for cross-reactivity. Challenges include distinguishing Lumican isoforms and ensuring specificity due to structural similarities within the SLRP family. Ongoing studies focus on therapeutic targeting of Lumican pathways in ECM-related pathologies.
×
